PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.45%
Positive revenue growth while 3088.T is negative. John Neff might see a notable competitive edge here.
8.06%
Positive gross profit growth while 3088.T is negative. John Neff would see a clear operational edge over the competitor.
14.43%
Positive EBIT growth while 3088.T is negative. John Neff might see a substantial edge in operational management.
17.38%
Positive operating income growth while 3088.T is negative. John Neff might view this as a competitive edge in operations.
50.76%
Positive net income growth while 3088.T is negative. John Neff might see a big relative performance advantage.
50.77%
Positive EPS growth while 3088.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
50.77%
Positive diluted EPS growth while 3088.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.29%
Dividend growth of 35.29% while 3088.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
6.12%
OCF growth above 1.5x 3088.T's 2.04%. David Dodd would confirm a clear edge in underlying cash generation.
6.12%
FCF growth above 1.5x 3088.T's 2.04%. David Dodd would verify if the firm’s strategic investments yield superior returns.
25.67%
10Y revenue/share CAGR under 50% of 3088.T's 112.16%. Michael Burry would suspect a lasting competitive disadvantage.
50.38%
5Y revenue/share CAGR at 50-75% of 3088.T's 70.08%. Martin Whitman would worry about a lagging mid-term growth trajectory.
15.60%
3Y revenue/share CAGR under 50% of 3088.T's 62.98%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.86%
Below 50% of 3088.T's 217.33%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
30.47%
5Y net income/share CAGR at 50-75% of 3088.T's 54.29%. Martin Whitman might see a shortfall in operational efficiency or brand power.
4.42%
Below 50% of 3088.T's 13.19%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
134.80%
10Y equity/share CAGR at 50-75% of 3088.T's 253.09%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
93.84%
5Y equity/share CAGR at 50-75% of 3088.T's 133.95%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
44.89%
Below 50% of 3088.T's 109.02%. Michael Burry suspects a serious short-term disadvantage in building book value.
283.33%
Below 50% of 3088.T's 600.00%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
155.56%
5Y dividend/share CAGR above 1.5x 3088.T's 16.67%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
91.67%
3Y dividend/share CAGR above 1.5x 3088.T's 0.00%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
32.94%
AR growth well above 3088.T's 41.09%. Michael Burry fears inflated revenue or higher default risk in the near future.
10.47%
We show growth while 3088.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
11.68%
Asset growth above 1.5x 3088.T's 0.17%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
3.71%
BV/share growth above 1.5x 3088.T's 0.78%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
187.81%
Debt growth far above 3088.T's 10.08%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-39.78%
We cut SG&A while 3088.T invests at 13.03%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.